YKST02 clinical trials
Also written YKST02.
How each study uses YKST02 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the YKST02 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- YKST02
- 4
Studies by the year they started
3 studies that test it; most in 2026 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Excyte Biopharma Ltd (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test YKST02.
- Dec 2026A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaPhase 1 · Excyte Biopharma Ltd
- Mar 2027A Study of YKST02 in Participants With Primary IgA NephropathyEarly Phase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Studies
Open first, then newest update. How each study uses YKST02 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 2Excyte Biopharma LtdNCT07695740Written as YKST02
- A Study of YKST02 in Participants With Primary IgA NephropathyRecruitingEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07498673Written as YKST02
- Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus ErythematosusNot yet recruitingPhase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07512947Written as YKST02
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Excyte Biopharma LtdNCT06574568Written as YKST02